vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and TECOGEN INC. (TGEN). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $5.3M, roughly 1.7× TECOGEN INC.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -75.1%, a 14.8% gap on every dollar of revenue. On growth, TECOGEN INC. posted the faster year-over-year revenue change (-12.5% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-2.6M). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -7.3%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
PLX vs TGEN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $5.3M |
| Net Profit | $-5.5M | $-4.0M |
| Gross Margin | 49.4% | 36.8% |
| Operating Margin | -51.1% | -77.8% |
| Net Margin | -60.3% | -75.1% |
| Revenue YoY | -49.9% | -12.5% |
| Net Profit YoY | -184.8% | -236.7% |
| EPS (diluted) | $-0.06 | $-0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $5.3M | ||
| Q3 25 | $17.9M | $7.2M | ||
| Q2 25 | $15.7M | $7.3M | ||
| Q1 25 | $10.1M | $7.3M | ||
| Q4 24 | $18.2M | $6.1M | ||
| Q3 24 | $18.0M | $5.6M | ||
| Q2 24 | $13.5M | $4.7M | ||
| Q1 24 | — | $6.2M |
| Q4 25 | $-5.5M | $-4.0M | ||
| Q3 25 | $2.4M | $-2.1M | ||
| Q2 25 | $164.0K | $-1.5M | ||
| Q1 25 | $-3.6M | $-659.9K | ||
| Q4 24 | $6.5M | $-1.2M | ||
| Q3 24 | $3.2M | $-930.4K | ||
| Q2 24 | $-2.2M | $-1.5M | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | 49.4% | 36.8% | ||
| Q3 25 | 53.4% | 30.4% | ||
| Q2 25 | 62.5% | 33.8% | ||
| Q1 25 | 19.1% | 44.3% | ||
| Q4 24 | 78.7% | 45.0% | ||
| Q3 24 | 53.4% | 44.1% | ||
| Q2 24 | 29.8% | 44.0% | ||
| Q1 24 | — | 41.6% |
| Q4 25 | -51.1% | -77.8% | ||
| Q3 25 | 11.9% | -29.2% | ||
| Q2 25 | 7.5% | -19.4% | ||
| Q1 25 | -41.0% | -8.2% | ||
| Q4 24 | 39.6% | -18.7% | ||
| Q3 24 | 22.2% | -15.5% | ||
| Q2 24 | -18.0% | -31.2% | ||
| Q1 24 | — | -17.0% |
| Q4 25 | -60.3% | -75.1% | ||
| Q3 25 | 13.2% | -29.7% | ||
| Q2 25 | 1.0% | -20.1% | ||
| Q1 25 | -35.8% | -9.1% | ||
| Q4 24 | 35.6% | -19.5% | ||
| Q3 24 | 18.0% | -16.5% | ||
| Q2 24 | -16.4% | -32.5% | ||
| Q1 24 | — | -17.9% |
| Q4 25 | $-0.06 | $-0.14 | ||
| Q3 25 | $0.03 | $-0.07 | ||
| Q2 25 | $0.00 | $-0.06 | ||
| Q1 25 | $-0.05 | $-0.03 | ||
| Q4 24 | $0.10 | $-0.05 | ||
| Q3 24 | $0.03 | $-0.04 | ||
| Q2 24 | $-0.03 | $-0.06 | ||
| Q1 24 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $12.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $21.6M |
| Total Assets | $82.3M | $37.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $12.4M | ||
| Q3 25 | $13.6M | $15.3M | ||
| Q2 25 | $17.9M | $1.6M | ||
| Q1 25 | $19.5M | $4.1M | ||
| Q4 24 | $19.8M | $5.4M | ||
| Q3 24 | $27.4M | $1.3M | ||
| Q2 24 | $23.4M | $841.9K | ||
| Q1 24 | — | $1.5M |
| Q4 25 | $48.2M | $21.6M | ||
| Q3 25 | $52.9M | $25.5M | ||
| Q2 25 | $49.9M | $9.1M | ||
| Q1 25 | $45.2M | $9.6M | ||
| Q4 24 | $43.2M | $10.2M | ||
| Q3 24 | $32.4M | $11.3M | ||
| Q2 24 | $28.6M | $12.2M | ||
| Q1 24 | — | $13.7M |
| Q4 25 | $82.3M | $37.0M | ||
| Q3 25 | $82.3M | $41.5M | ||
| Q2 25 | $78.5M | $28.4M | ||
| Q1 25 | $73.9M | $29.7M | ||
| Q4 24 | $73.4M | $31.1M | ||
| Q3 24 | $61.6M | $27.5M | ||
| Q2 24 | $91.5M | $27.2M | ||
| Q1 24 | — | $28.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-2.6M |
| Free Cash FlowOCF − Capex | $1.6M | $-2.6M |
| FCF MarginFCF / Revenue | 17.8% | -49.3% |
| Capex IntensityCapex / Revenue | 4.4% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $-10.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-2.6M | ||
| Q3 25 | $-3.7M | $-3.6M | ||
| Q2 25 | $-5.2M | $-2.6M | ||
| Q1 25 | $-5.1M | $-1.2M | ||
| Q4 24 | $4.0M | $4.2M | ||
| Q3 24 | $4.1M | $-207.3K | ||
| Q2 24 | $-3.6M | $-157.9K | ||
| Q1 24 | — | $248.2K |
| Q4 25 | $1.6M | $-2.6M | ||
| Q3 25 | $-4.2M | $-3.6M | ||
| Q2 25 | $-5.7M | $-2.7M | ||
| Q1 25 | $-5.4M | $-1.3M | ||
| Q4 24 | $3.6M | $4.0M | ||
| Q3 24 | $4.0M | $-489.6K | ||
| Q2 24 | $-3.8M | $-609.6K | ||
| Q1 24 | — | $143.3K |
| Q4 25 | 17.8% | -49.3% | ||
| Q3 25 | -23.7% | -50.6% | ||
| Q2 25 | -36.2% | -37.7% | ||
| Q1 25 | -53.0% | -17.9% | ||
| Q4 24 | 19.6% | 66.6% | ||
| Q3 24 | 22.4% | -8.7% | ||
| Q2 24 | -28.1% | -12.9% | ||
| Q1 24 | — | 2.3% |
| Q4 25 | 4.4% | 0.9% | ||
| Q3 25 | 2.8% | 1.0% | ||
| Q2 25 | 2.8% | 2.0% | ||
| Q1 25 | 3.0% | 1.8% | ||
| Q4 24 | 2.3% | 2.1% | ||
| Q3 24 | 0.5% | 5.0% | ||
| Q2 24 | 1.3% | 9.6% | ||
| Q1 24 | — | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
TGEN
| Installation Services | $4.5M | 84% |
| Products Segment | $460.5K | 9% |
| Other | $394.7K | 7% |
